Value of an Integral Color Scale on Urine Collection Bags Versus Use of a Strip in Description of Hematuria. (HEMAPOCHE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Nîmes, France, 30029
- CHU Nîmes
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The participant is at least 18 year old
- Nurses recruited voluntarily in the CHU Nimes outside of the Urology department of any duration of experience
- Urologist working in the Languedoc-Roussillon region
Exclusion Criteria:
- The participant has color-blindness
- Nurse or urologist from the urology department of Nimes
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Nurses
|
Use of Hemapoche scale to assess hematuria in reference samples
Use of Hemastick scale to assess hematuria in reference samples
Describe color of reference sample
|
|
Urologists
|
Use of Hemapoche scale to assess hematuria in reference samples
Use of Hemastick scale to assess hematuria in reference samples
Describe color of reference sample
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intra-user concordance in assessment of hematuria score measured by Hemapoche
Time Frame: Baseline
|
Kappa coefficient
|
Baseline
|
|
Intra-user concordance in assessment of hematuria score measured by Hemostick
Time Frame: Baseline
|
Kappa coefficient
|
Baseline
|
|
Intra-user concordance in assessment of hematuria described by color of urine
Time Frame: Baseline
|
Kappa coefficient
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concordance between nurses versus doctors in assessment of hematuria score measured by Hemapoche
Time Frame: Baseline
|
Kappa coefficient
|
Baseline
|
|
Concordance between nurses versus doctors in assessment of hematuria score measured by Hemastick
Time Frame: Baseline
|
Kappa coefficient
|
Baseline
|
|
Concordance between nurses versus doctors in assessment of hematuria described by color
Time Frame: Baseline
|
Kappa coefficient
|
Baseline
|
|
Time needed to characterize hematuria when using Hemapoche
Time Frame: Baseline
|
Seconds (less than one minute)
|
Baseline
|
|
Time needed to characterize hematuria when using Hemostick
Time Frame: Baseline
|
Seconds (less than one minute)
|
Baseline
|
|
Time needed to characterize hematuria when using color description
Time Frame: Baseline
|
Seconds (less than one minute)
|
Baseline
|
|
Satisfaction of medical staff in using Hemapoche medical device
Time Frame: Baseline
|
Visual analog scale (0-10)
|
Baseline
|
|
Usability scale of Hemapoche device according to medical staff
Time Frame: Baseline
|
System usability scale (0-10)
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Armand Chevrot, MD, CHU Nîmes
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIMAO/2017-02/AC-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematuria
-
NCT07312461Recruiting
-
NCT03033160UnknownAsymptomatic Microscopic Hematuria
-
NCT02213757TerminatedMicroscopic Hematuria
-
NCT01615315CompletedMicroscopic Hematuria | Asymptomatic General Population
-
NCT00975455Completed
-
NCT04332731Active, not recruitingLoin Pain-Hematuria Syndrome
-
NCT01600443Terminated
-
NCT05220189RecruitingBladder Cancer | Hematuria; Benign
-
NCT07395037RecruitingUrologic Diseases | Bladder Cancer | Urothelial Carcinoma | Renal Cancer | Hematuria | Hematuria; Benign
-
NCT04275297CompletedInterstitial Cystitis | Cystitis, Interstitial | Painful Bladder Syndrome | Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Bladder Pain Syndrome | Chronic Interstitial Cystitis | Interstitial Cystitis, Chronic | Cystitis, Chronic Interstitial | Interstitial Cystitis (Chronic) With Hematuria